Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 816246

IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy


Jeremić, Branislav; Fidarova, Elena; Sharma, V.; Faheem, M.; Ameira, A.; Nasr, Ben Amar; Frobe, Ana; Lau, F.N.; Brincat, S.; Jones, G.
IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy // Radiotherapy and oncology, 116 (2015), 1; 21-26 doi:10.1016/j.radonc.2015.06.017 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 816246 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy

Autori
Jeremić, Branislav ; Fidarova, Elena ; Sharma, V. ; Faheem, M. ; Ameira, A. ; Nasr, Ben Amar ; Frobe, Ana ; Lau, F.N. ; Brincat, S. ; Jones, G.

Izvornik
Radiotherapy and oncology (0167-8140) 116 (2015), 1; 21-26

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
NSCLC ; locally advanced nonsmall cell lung canc ; radiotherapy ; chemotherapy ; randomized trial ; International Atomic Energy Agency

Sažetak
O optimize palliation in incurable locally advanced non-small cell lung cancer (NSCLC), the International Atomic Energy Agency conducted a prospective randomized study (NCT00864331) comparing protracted palliative radiotherapy (RT) course with chemotherapy (CHT) followed by short-course palliative RT. Treatment-naive patients with histologically confirmed NSCLC, stage IIIA/IIIB, received either 39 Gy in 13 fractions as RT alone (arm A, n = 31) or 2–3 platinum-based CHT cycles followed by 10 Gy in a single fraction or 16 Gy in 2 fractions separated by one week (arm B, n = 34). Primary outcome was overall survival. Treatment groups were balanced with respect to various variables. Median survival for all 65 patients was 8 months, while median survival was 7.1 and 8.1 months for the two arms, respectively (log-rank p = 0.4 by study arm, and p = 0.6 by Cox regression and stratified by country and sub-stage). One and three year survival rates for the two arms were 29%, and 9% and 41%, and 6%, respectively. There were no differences in any of the following endpoints: any failure, local failure, regional failure, contralateral thoracic failure, and distant failure between the two arms. High-grade (⩾3) toxicity was similar between the two arms. Symptoms, adverse events of any kind, KPS and body-mass index, were not different during treatment and during follow-up. There was no grade 5 toxicity. This incomplete and underpowered trial only hinted similar outcome between the treatment arms. Therefore, combined CHT-RT can perhaps be considered, in limited resource setting, where access to RT remains inadequate.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
KBC "Sestre Milosrdnice"

Profili:

Avatar Url Ana Fröbe (autor)

Poveznice na cjeloviti tekst rada:

doi www.sciencedirect.com doi.org

Citiraj ovu publikaciju:

Jeremić, Branislav; Fidarova, Elena; Sharma, V.; Faheem, M.; Ameira, A.; Nasr, Ben Amar; Frobe, Ana; Lau, F.N.; Brincat, S.; Jones, G.
IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy // Radiotherapy and oncology, 116 (2015), 1; 21-26 doi:10.1016/j.radonc.2015.06.017 (međunarodna recenzija, članak, znanstveni)
Jeremić, B., Fidarova, E., Sharma, V., Faheem, M., Ameira, A., Nasr, B., Frobe, A., Lau, F., Brincat, S. & Jones, G. (2015) IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy. Radiotherapy and oncology, 116 (1), 21-26 doi:10.1016/j.radonc.2015.06.017.
@article{article, author = {Jeremi\'{c}, Branislav and Fidarova, Elena and Sharma, V. and Faheem, M. and Ameira, A. and Nasr, Ben Amar and Frobe, Ana and Lau, F.N. and Brincat, S. and Jones, G.}, year = {2015}, pages = {21-26}, DOI = {10.1016/j.radonc.2015.06.017}, keywords = {NSCLC, locally advanced nonsmall cell lung canc, radiotherapy, chemotherapy, randomized trial, International Atomic Energy Agency}, journal = {Radiotherapy and oncology}, doi = {10.1016/j.radonc.2015.06.017}, volume = {116}, number = {1}, issn = {0167-8140}, title = {IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy}, keyword = {NSCLC, locally advanced nonsmall cell lung canc, radiotherapy, chemotherapy, randomized trial, International Atomic Energy Agency} }
@article{article, author = {Jeremi\'{c}, Branislav and Fidarova, Elena and Sharma, V. and Faheem, M. and Ameira, A. and Nasr, Ben Amar and Frobe, Ana and Lau, F.N. and Brincat, S. and Jones, G.}, year = {2015}, pages = {21-26}, DOI = {10.1016/j.radonc.2015.06.017}, keywords = {NSCLC, locally advanced nonsmall cell lung canc, radiotherapy, chemotherapy, randomized trial, International Atomic Energy Agency}, journal = {Radiotherapy and oncology}, doi = {10.1016/j.radonc.2015.06.017}, volume = {116}, number = {1}, issn = {0167-8140}, title = {IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy}, keyword = {NSCLC, locally advanced nonsmall cell lung canc, radiotherapy, chemotherapy, randomized trial, International Atomic Energy Agency} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka::


  • CA Search (Chemical Abstracts)
  • EMBASE (Excerpta Medica)
  • Elsevier BIOBASE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font